You can start by taking our free assessment quiz to determine your eligibility for semaglutide and receive a personalized treatment plan tailored to your needs
(1) Because semaglutide can assist weight loss, it may also reduce the risk of heart disease, diabetes and cancer in overweight people
11.2 KNOWLEDGESTORE: MARKETSANDMARKETS SUBSCRIPTION PORTAL 11.3 CUSTOMIZATION OPTIONS TABLE 1 BIOSIMILARS MARKET: INCLUSIONS & EXCLUSIONS TABLE 2 IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS TABLE 3 BIOSIMILARS MARKET: RISK ANALYSIS TABLE 4 BIOSIMILARS MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS TABLE 5 LIST OF KEY BIOSIMILARS APPROVED BY MAJOR PLAYERS, 20232025 TABLE 6 LIST OF IMPENDING AND ONGOING PATENT EXPIRIES OF BLOCKBUSTER BIOLOGICS, 20232035 TABLE 7 COMPARISON AMONG DIFFERENT DRUG TYPES, INVESTMENTS, APPROVAL TIMES, AND NUMBER OF PATIENTS IN STUDIES TABLE 8 BIOSIMILARS MARKET: ROLE IN ECOSYSTEM TABLE 9 BIOSIMILARS MARKET: NUMBER OF PATENTS FILED (APPLIED/GRANTED), 20142024 TABLE 10 BIOSIMILARS MARKET: INDICATIVE LIST OF KEY PATENTS, 2024 TABLE 11 BIOSIMILARS MARKET: PRODUCTS IN CLINICAL PIPELINE TABLE 12 BIOSIMILARS MARKET: LIST OF KEY BIOLOGICS TO GO OFF-PATENT, 20252035 TABLE 13 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS TABLE 14 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS TABLE 15 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS TABLE 16 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS TABLE 17 BIOSIMILARS MARKET: COUNTRY/REGION-WISE REGULATORY FRAMEWORK TABLE 18 US: REIMBURSEMENT SCENARIO FOR RECENTLY LAUNCHED BIOSIMILARS, 20242025 TABLE 19 US: REIMBURSEMENT CODES FOR BIOSIMILAR PRODUCTS TABLE 20 AVERAGE SELLING PRICE TREND OF BIOSIMILAR PRODUCTS, BY KEY PLAYER, 20222024 (USD) TABLE 21 AVERAGE SELLING PRICE TREND OF BIOSIMILAR PRODUCTS, BY REGION, 20222024 (USD) TABLE 22 BIOSIMILARS MARKET: DETAILED LIST OF KEY CONFERENCES & EVENTS, JANUARY 2025DECEMBER 2026 TABLE 23 BIOSIMILARS MARKET: PORTERS FIVE FORCES TABLE 24 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY DRUG CLASS (%) TABLE 25 KEY BUYING CRITERIA FOR BIOSIMILAR PRODUCTS, BY END USER TABLE 26 US ADJUSTED RECIPROCAL TARIFF RATES TABLE 27 BIOSIMILARS MARKET, BY DRUG CLASS, 20232035 (USD MILLION) TABLE 28 BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 20232035 (USD MILLION) TABLE 29 BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 20232035 (USD MILLION) TABLE 30 NORTH AMERICA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 20232035 (USD MILLION) TABLE 31 EUROPE: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 20232035 (USD MILLION) TABLE 32 ASIA PACIFIC: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 20232035 (USD MILLION) TABLE 33 LATIN AMERICA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 20232035 (USD MILLION) TABLE 34 MIDDLE EAST: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 20232035 (USD MILLION) TABLE 35 RITUXIMAB MARKET, BY REGION, 20232035 (USD MILLION) TABLE 36 NORTH AMERICA: RITUXIMAB MARKET, BY COUNTRY, 20232035 (USD MILLION) TABLE 37 EUROPE: RITUXIMAB MARKET, BY COUNTRY, 20232035 (USD MILLION) TABLE 38 ASIA PACIFIC: RITUXIMAB MARKET, BY COUNTRY, 20232035 (USD MILLION) TABLE 39 LATIN AMERICA: RITUXIMAB MARKET, BY COUNTRY, 20232035 (USD MILLION) TABLE 40 MIDDLE EAST: RITUXIMAB MARKET, BY REGION, 20232035 (USD MILLION) TABLE 41 INFLIXIMAB MARKET, BY REGION, 20232035 (USD MILLION) TABLE 42 NORTH AMERICA: INFLIXIMAB MARKET, BY COUNTRY, 20232035 (USD MILLION) TABLE 43 EUROPE: INFLIXIMAB MARKET, BY COUNTRY, 20232035 (USD MILLION) TABLE 44 ASIA PACIFIC: INFLIXIMAB MARKET, BY COUNTRY, 20232035 (USD MILLION) TABLE 45 LATIN AMERICA: INFLIXIMAB MARKET, BY COUNTRY, 20232035 (USD MILLION) TABLE 46 MIDDLE EAST: INFLIXIMAB MARKET, BY REGION, 20232035 (USD MILLION) TABLE 47 ADALIMUMAB MARKET, BY REGION, 20232035 (USD MILLION) TABLE 48 NORTH AMERICA: ADALIMUMAB MARKET, BY COUNTRY, 20232035 (USD MILLION) TABLE 49 EUROPE: ADALIMUMAB MARKET, BY COUNTRY, 20232035 (USD MILLION) TABLE 50 ASIA PACIFIC: ADALIMUMAB MARKET, BY COUNTRY, 20232035 (USD MILLION) TABLE 51 LATIN AMERICA: ADALIMUMAB MARKET, BY COUNTRY, 20232035 (USD MILLION) TABLE 52 MIDDLE EAST: ADALIMUMAB MARKET, BY REGION, 20232035 (USD MILLION) TABLE 53 TRASTUZUMAB MARKET, BY REGION, 20232035 (USD MILLION) TABLE 54 NORTH AMERICA: TRASTUZUMAB MARKET, BY COUNTRY, 20232035 (USD MILLION) TABLE 55 EUROPE: TRASTUZUMAB MARKET, BY COUNTRY, 20232035 (USD MILLION) TABLE 56 ASIA PACIFIC: TRASTUZUMAB MARKET, BY COUNTRY, 20232035 (USD MILLION) TABLE 57 LATIN AMERICA: TRASTUZUMAB MARKET, BY COUNTRY, 20232035 (USD MILLION) TABLE 58 MIDDLE EAST: TRASTUZUMAB MARKET, BY REGION, 20232035 (USD MILLION) TABLE 59 PEMBROLIZUMAB MARKET, BY REGION, 20232035 (USD MILLION) TABLE 60 NORTH AMERICA: PEMBROLIZUMAB MARKET, BY COUNTRY, 20232035 (USD MILLION) TABLE 61 EUROPE: PEMBROLIZUMAB MARKET, BY COUNTRY, 20232035 (USD MILLION) TABLE 62 ASIA PACIFIC: PEMBROLIZUMAB MARKET, BY COUNTRY, 20232035 (USD MILLION) TABLE 63 LATIN AMERICA: PEMBROLIZUMAB MARKET, BY COUNTRY, 20232035 (USD MILLION) TABLE 64 MIDDLE EAST: PEMBROLIZUMAB MARKET, BY REGION, 20232035 (USD MILLION) TABLE 65 DUPILUMAB MARKET, BY REGION, 20232035 (USD MILLION) TABLE 66 NORTH AMERICA: DUPILUMAB MARKET, BY COUNTRY, 20232035 (USD MILLION) TABLE 67 EUROPE: DUPILUMAB MARKET, BY COUNTRY, 20232035 (USD MILLION) TABLE 68 ASIA PACIFIC: DUPILUMAB MARKET, BY COUNTRY, 20232035 (USD MILLION) TABLE 69 LATIN AMERICA: DUPILUMAB MARKET, BY COUNTRY, 20232035 (USD MILLION) TABLE 70 MIDDLE EAST: DUPILUMAB MARKET, BY REGION, 20232035 (USD MILLION) TABLE 71 USTEKINUMAB MARKET, BY REGION, 20232035 (USD MILLION) TABLE 72 NORTH AMERICA: USTEKINUMAB MARKET, BY COUNTRY, 20232035 (USD MILLION) TABLE 73 EUROPE: USTEKINUMAB MARKET, BY COUNTRY, 20232035 (USD MILLION) TABLE 74 ASIA PACIFIC: USTEKINUMAB MARKET, BY COUNTRY, 20232035 (USD MILLION) TABLE 75 LATIN AMERICA: USTEKINUMAB MARKET, BY COUNTRY, 20232035 (USD MILLION) TABLE 76 MIDDLE EAST: USTEKINUMAB MARKET, BY REGION, 20232035 (USD MILLION) TABLE 77 RISANKIZUMAB MARKET, BY REGION, 20232035 (USD MILLION) TABLE 78 NORTH AMERICA: RISANKIZUMAB MARKET, BY COUNTRY, 20232035 (USD MILLION) TABLE 79 EUROPE: RISANKIZUMAB MARKET, BY COUNTRY, 20232035 (USD MILLION) TABLE 80 ASIA PACIFIC: RISANKIZUMAB MARKET, BY COUNTRY, 20232035 (USD MILLION) TABLE 81 LATIN AMERICA: RISANKIZUMAB MARKET, BY COUNTRY, 20232035 (USD MILLION) TABLE 82 MIDDLE EAST: RISANKIZUMAB MARKET, BY REGION, 20232035 (USD MILLION) TABLE 83 OTHER MONOCLONAL ANTIBODIES MARKET, BY REGION, 20232035 (USD MILLION) TABLE 84 NORTH AMERICA: OTHER MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 20232035 (USD MILLION) TABLE 85 EUROPE: OTHER MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 20232035 (USD MILLION) TABLE 86 ASIA PACIFIC: OTHER MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 20232035 (USD MILLION) TABLE 87 LATIN AMERICA: OTHER MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 20232035 (USD MILLION) TABLE 88 MIDDLE EAST: OTHER MONOCLONAL ANTIBODIES MARKET, BY REGION, 20232035 (USD MILLION) TABLE 89 LIST OF APPROVED BIOSIMILARS FOR GRANULOCYTE COLONY- STIMULATING FACTOR (G-CSF) TABLE 90 BIOSIMILARS MARKET FOR GRANULOCYTE COLONY-STIMULATING FACTOR, BY REGION, 20232035 (USD MILLION) TABLE 91 NORTH AMERICA: BIOSIMILARS MARKET FOR GRANULOCYTE COLONY-STIMULATING FACTOR, BY COUNTRY, 20232035 (USD MILLION) TABLE 92 EUROPE: BIOSIMILARS MARKET FOR GRANULOCYTE COLONY-STIMULATING FACTOR, BY COUNTRY, 20232035 (USD MILLION) TABLE 93 ASIA PACIFIC: BIOSIMILARS MARKET FOR GRANULOCYTE COLONY-STIMULATING FACTOR, BY COUNTRY, 20232035 (USD MILLION) TABLE 94 LATIN AMERICA: BIOSIMILARS MARKET FOR GRANULOCYTE COLONY-STIMULATING FACTOR, BY COUNTRY, 20232035 (USD MILLION) TABLE 95 MIDDLE EAST: BIOSIMILARS MARKET FOR GRANULOCYTE COLONY-STIMULATING FACTOR, BY REGION, 20232035 (USD MILLION) TABLE 96 BIOSIMILARS MARKET FOR INSULIN, BY REGION, 20232035 (USD MILLION) TABLE 97 NORTH AMERICA: BIOSIMILARS MARKET FOR INSULIN, BY COUNTRY, 20232035 (USD MILLION) TABLE 98 EUROPE: BIOSIMILARS MARKET FOR INSULIN, BY COUNTRY, 20232035 (USD MILLION) TABLE 99 ASIA PACIFIC: BIOSIMILARS MARKET FOR INSULIN, BY COUNTRY, 20232035 (USD MILLION) TABLE 100 LATIN AMERICA: BIOSIMILARS MARKET FOR INSULIN, BY COUNTRY, 20232035 (USD MILLION) TABLE 101 MIDDLE EAST: BIOSIMILARS MARKET FOR INSULIN, BY REGION, 20232035 (USD MILLION) TABLE 102 LIST OF APPROVED BIOSIMILARS FOR ERYTHROPOIETIN TABLE 103 BIOSIMILARS MARKET FOR ERYTHROPOIETIN, BY REGION, 20232035 (USD MILLION) TABLE 104 NORTH AMERICA: BIOSIMILARS MARKET FOR ERYTHROPOIETIN, BY COUNTRY, 20232035 (USD MILLION) TABLE 105 EUROPE: BIOSIMILARS MARKET FOR ERYTHROPOIETIN, BY COUNTRY, 20232035 (USD MILLION) TABLE 106 ASIA PACIFIC: BIOSIMILARS MARKET FOR ERYTHROPOIETIN, BY COUNTRY, 20232035 (USD MILLION) TABLE 107 LATIN AMERICA: BIOSIMILARS MARKET FOR ERYTHROPOIETIN, BY COUNTRY, 20232035 (USD MILLION) TABLE 108 MIDDLE EAST: BIOSIMILARS MARKET FOR ERYTHROPOIETIN, BY REGION, 20232035 (USD MILLION) TABLE 109 BIOSIMILARS MARKET FOR RECOMBINANT HUMAN GROWTH HORMONE, BY REGION, 20232035 (USD MILLION) TABLE 110 NORTH AMERICA: BIOSIMILARS MARKET FOR RECOMBINANT HUMAN GROWTH HORMONE, BY COUNTRY, 20232035 (USD MILLION) TABLE 111 EUROPE: BIOSIMILARS MARKET FOR RECOMBINANT HUMAN GROWTH HORMONE, BY COUNTRY, 20232035 (USD MILLION) TABLE 112 ASIA PACIFIC: BIOSIMILARS MARKET FOR RECOMBINANT HUMAN GROWTH HORMONE, BY COUNTRY, 20232035 (USD MILLION) TABLE 113 LATIN AMERICA: BIOSIMILARS MARKET FOR RECOMBINANT HUMAN GROWTH HORMONE, BY COUNTRY, 20232035 (USD MILLION) TABLE 114 MIDDLE EAST: BIOSIMILARS MARKET FOR RECOMBINANT HUMAN GROWTH HORMONE, BY REGION, 20232035 (USD MILLION) TABLE 115 BIOSIMILARS MARKET FOR ETANERCEPT, BY REGION, 20232035 (USD MILLION) TABLE 116 NORTH AMERICA: BIOSIMILARS MARKET FOR ETANERCEPT, BY COUNTRY, 20232035 (USD MILLION) TABLE 117 EUROPE: BIOSIMILARS MARKET FOR ETANERCEPT, BY COUNTRY, 20232035 (USD MILLION) TABLE 118 ASIA PACIFIC: BIOSIMILARS MARKET FOR ETANERCEPT, BY COUNTRY, 20232035 (USD MILLION) TABLE 119 LATIN AMERICA: BIOSIMILARS MARKET FOR ETANERCEPT, BY COUNTRY, 20232035 (USD MILLION) TABLE 120 MIDDLE EAST: BIOSIMILARS MARKET FOR ETANERCEPT, BY REGION, 20232035 (USD MILLION) TABLE 121 BIOSIMILARS MARKET FOR FOLLITROPIN, BY REGION, 20232035 (USD MILLION) TABLE 122 NORTH AMERICA: BIOSIMILARS MARKET FOR FOLLITROPIN, BY COUNTRY, 20232035 (USD MILLION) TABLE 123 EUROPE: BIOSIMILARS MARKET FOR FOLLITROPIN, BY COUNTRY, 20232035 (USD MILLION) TABLE 124 ASIA PACIFIC: BIOSIMILARS MARKET FOR FOLLITROPIN, BY COUNTRY, 20232035 (USD MILLION) TABLE 125 LATIN AMERICA: BIOSIMILARS MARKET FOR FOLLITROPIN, BY COUNTRY, 20232035 (USD MILLION) TABLE 126 MIDDLE EAST: BIOSIMILARS MARKET FOR FOLLITROPIN, BY REGION, 20232035 (USD MILLION) TABLE 127 BIOSIMILARS MARKET FOR TERIPARATIDE, BY REGION, 20232035 (USD MILLION) TABLE 128 NORTH AMERICA: BIOSIMILARS MARKET FOR TERIPARATIDE, BY COUNTRY, 20232035 (USD MILLION) TABLE 129 EUROPE: BIOSIMILARS MARKET FOR TERIPARATIDE, BY COUNTRY, 20232035 (USD MILLION) TABLE 130 ASIA PACIFIC: BIOSIMILARS MARKET FOR TERIPARATIDE, BY COUNTRY, 20232035 (USD MILLION) TABLE 131 LATIN AMERICA: BIOSIMILARS MARKET FOR TERIPARATIDE, BY COUNTRY, 20232035 (USD MILLION) TABLE 132 MIDDLE EAST: BIOSIMILARS MARKET FOR TERIPARATIDE, BY REGION, 20232035 (USD MILLION) TABLE 133 BIOSIMILARS MARKET FOR INTERFERONS, BY REGION, 20232035 (USD MILLION) TABLE 134 NORTH AMERICA: BIOSIMILARS MARKET FOR INTERFERONS, BY COUNTRY, 20232035 (USD MILLION) TABLE 135 EUROPE: BIOSIMILARS MARKET FOR INTERFERONS, BY COUNTRY, 20232035 (USD MILLION) TABLE 136 ASIA PACIFIC: BIOSIMILARS MARKET FOR INTERFERONS, BY COUNTRY, 20232035 (USD MILLION) TABLE 137 LATIN AMERICA: BIOSIMILARS MARKET FOR INTERFERONS, BY COUNTRY, 20232035 (USD MILLION) TABLE 138 MIDDLE EAST: BIOSIMILARS MARKET FOR INTERFERONS, BY REGION, 20232035 (USD MILLION) TABLE 139 BIOSIMILARS MARKET FOR ANTICOAGULANTS, BY REGION, 20232035 (USD MILLION) TABLE 140 NORTH AMERICA: BIOSIMILARS MARKET FOR ANTICOAGULANTS, BY COUNTRY, 20232035 (USD MILLION) TABLE 141 EUROPE: BIOSIMILARS MARKET FOR ANTICOAGULANTS, BY COUNTRY, 20232035 (USD MILLION) TABLE 142 ASIA PACIFIC: BIOSIMILARS MARKET FOR ANTICOAGULANTS, BY COUNTRY, 20232035 (USD MILLION) TABLE 143 LATIN AMERICA: BIOSIMILARS MARKET FOR ANTICOAGULANTS, BY COUNTRY, 20232035 (USD MILLION) TABLE 144 MIDDLE EAST: BIOSIMILARS MARKET FOR ANTICOAGULANTS, BY REGION, 20232035 (USD MILLION) TABLE 145 BIOSIMILARS MARKET FOR AFLIBERCEPT, BY REGION, 20232035 (USD MILLION) TABLE 146 NORTH AMERICA: BIOSIMILARS MARKET FOR AFLIBERCEPT, BY COUNTRY, 20232035 (USD MILLION) TABLE 147 EUROPE: BIOSIMILARS MARKET FOR AFLIBERCEPT, BY COUNTRY, 20232035 (USD MILLION) TABLE 148 ASIA PACIFIC: BIOSIMILARS MARKET FOR AFLIBERCEPT, BY COUNTRY, 20232035 (USD MILLION) TABLE 149 LATIN AMERICA: BIOSIMILARS MARKET FOR AFLIBERCEPT, BY COUNTRY, 20232035 (USD MILLION) TABLE 150 MIDDLE EAST: BIOSIMILARS MARKET FOR AFLIBERCEPT, BY REGION, 20232035 (USD MILLION) TABLE 151 BIOSIMILARS MARKET FOR GLP-1 ANTAGONIST, BY REGION, 20232035 (USD MILLION) TABLE 152 NORTH AMERICA: BIOSIMILARS MARKET FOR GLP-1 ANTAGONIST, BY COUNTRY, 20232035 (USD MILLION) TABLE 153 EUROPE: BIOSIMILARS MARKET FOR GLP-1 ANTAGONIST, BY COUNTRY, 20232035 (USD MILLION) TABLE 154 ASIA PACIFIC: BIOSIMILARS MARKET FOR GLP-1 ANTAGONIST, BY COUNTRY, 20232035 (USD MILLION) TABLE 155 LATIN AMERICA: BIOSIMILARS MARKET FOR GLP-1 ANTAGONIST, BY COUNTRY, 20232035 (USD MILLION) TABLE 156 MIDDLE EAST: BIOSIMILARS MARKET FOR GLP-1 ANTAGONIST, BY REGION, 20232035 (USD MILLION) TABLE 157 BIOSIMILARS MARKET FOR OTHER DRUG CLASSES, BY REGION, 20232035 (USD MILLION) TABLE 158 NORTH AMERICA: BIOSIMILARS MARKET FOR OTHER DRUG CLASSES, BY COUNTRY, 20232035 (USD MILLION) TABLE 159 EUROPE: BIOSIMILARS MARKET FOR OTHER DRUG CLASSES, BY COUNTRY, 20232035 (USD MILLION) TABLE 160 ASIA PACIFIC: BIOSIMILARS MARKET FOR OTHER DRUG CLASSES, BY COUNTRY, 20232035 (USD MILLION) TABLE 161 LATIN AMERICA: BIOSIMILARS MARKET FOR OTHER DRUG CLASSES, BY COUNTRY, 20232035 (USD MILLION) TABLE 162 MIDDLE EAST: BIOSIMILARS MARKET FOR OTHER DRUG CLASSES, BY REGION, 20232035 (USD MILLION) TABLE 163 BIOSIMILARS MARKET, BY INDICATION, 20232035 (USD MILLION) TABLE 164 BIOSIMILARS MARKET FOR ONCOLOGY, BY REGION, 20232035 (USD MILLION) TABLE 165 NORTH AMERICA: BIOSIMILARS MARKET FOR ONCOLOGY, BY COUNTRY, 20232035 (USD MILLION) TABLE 166 EUROPE: BIOSIMILARS MARKET FOR ONCOLOGY, BY COUNTRY, 20232035 (USD MILLION) TABLE 167 ASIA PACIFIC: BIOSIMILARS MARKET FOR ONCOLOGY, BY COUNTRY, 20232035 (USD MILLION) TABLE 168 LATIN AMERICA: BIOSIMILARS MARKET FOR ONCOLOGY, BY COUNTRY, 20232035 (USD MILLION) TABLE 169 MIDDLE EAST: BIOSIMILARS MARKET FOR ONCOLOGY, BY REGION, 20232035 (USD MILLION) TABLE 170 BIOSIMILARS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY REGION, 20232035 (USD MILLION) TABLE 171 NORTH AMERICA: BIOSIMILARS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY COUNTRY, 20232035 (USD MILLION) TABLE 172 EUROPE: BIOSIMILARS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY COUNTRY, 20232035 (USD MILLION) TABLE 173 ASIA PACIFIC: BIOSIMILARS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY COUNTRY, 20232035 (USD MILLION) TABLE 174 LATIN AMERICA: BIOSIMILARS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY COUNTRY, 20232035 (USD MILLION) TABLE 175 MIDDLE EAST: BIOSIMILARS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY REGION, 20232035 (USD MILLION) TABLE 176 BIOSIMILARS MARKET FOR CHRONIC DISEASES, BY REGION, 20232035 (USD MILLION) TABLE 177 NORTH AMERICA: BIOSIMILARS MARKET FOR CHRONIC DISEASES, BY COUNTRY, 20232035 (USD MILLION) TABLE 178 EUROPE: BIOSIMILARS MARKET FOR CHRONIC DISEASES, BY COUNTRY, 20232035 (USD MILLION) TABLE 179 ASIA PACIFIC: BIOSIMILARS MARKET FOR CHRONIC DISEASES, BY COUNTRY, 20232035 (USD MILLION) TABLE 180 LATIN AMERICA: BIOSIMILARS MARKET FOR CHRONIC DISEASES, BY COUNTRY, 20232035 (USD MILLION) TABLE 181 MIDDLE EAST: BIOSIMILARS MARKET FOR CHRONIC DISEASES, BY REGION, 20232035 (USD MILLION) TABLE 182 BIOSIMILARS MARKET FOR BLOOD DISORDERS, BY REGION, 20232035 (USD MILLION) TABLE 183 NORTH AMERICA: BIOSIMILARS MARKET FOR BLOOD DISORDERS, BY COUNTRY, 20232035 (USD MILLION) TABLE 184 EUROPE: BIOSIMILARS MARKET FOR BLOOD DISORDERS, BY COUNTRY, 20232035 (USD MILLION) TABLE 185 ASIA PACIFIC: BIOSIMILARS MARKET FOR BLOOD DISORDERS, BY COUNTRY, 20232035 (USD MILLION) TABLE 186 LATIN AMERICA: BIOSIMILARS MARKET FOR BLOOD DISORDERS, BY COUNTRY, 20232035 (USD MILLION) TABLE 187 MIDDLE EAST: BIOSIMILARS MARKET FOR BLOOD DISORDERS, BY REGION, 20232035 (USD MILLION) TABLE 188 BIOSIMILARS MARKET FOR GROWTH HORMONE DEFICIENCY, BY REGION, 20232035 (USD MILLION) TABLE 189 NORTH AMERICA: BIOSIMILARS MARKET FOR GROWTH HORMONE DEFICIENCY, BY COUNTRY, 20232035 (USD MILLION) TABLE 190 EUROPE: BIOSIMILARS MARKET FOR GROWTH HORMONE DEFICIENCY, BY COUNTRY, 20232035 (USD MILLION) TABLE 191 ASIA PACIFIC: BIOSIMILARS MARKET FOR GROWTH HORMONE DEFICIENCY, BY COUNTRY, 20232035 (USD MILLION) TABLE 192 LATIN AMERICA: BIOSIMILARS MARKET FOR GROWTH HORMONE DEFICIENCY, BY COUNTRY, 20232035 (USD MILLION) TABLE 193 MIDDLE EAST: BIOSIMILARS MARKET FOR GROWTH HORMONE DEFICIENCY, BY REGION, 20232035 (USD MILLION) TABLE 194 BIOSIMILARS MARKET FOR INFECTIOUS DISEASES, BY REGION, 20232035 (USD MILLION) TABLE 195 NORTH AMERICA: BIOSIMILARS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 20232035 (USD MILLION) TABLE 196 EUROPE: BIOSIMILARS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 20232035 (USD MILLION) TABLE 197 ASIA PACIFIC: BIOSIMILARS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 20232035 (USD MILLION) TABLE 198 LATIN AMERICA: BIOSIMILARS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 20232035 (USD MILLION) TABLE 199 MIDDLE EAST: BIOSIMILARS MARKET FOR INFECTIOUS DISEASES, BY REGION, 20232035 (USD MILLION) TABLE 200 BIOSIMILARS MARKET FOR TYPE II DIABETES, BY REGION, 20232035 (USD MILLION) TABLE 201 NORTH AMERICA: BIOSIMILARS MARKET FOR TYPE II DIABETES, BY COUNTRY, 20232035 (USD MILLION) TABLE 202 EUROPE: BIOSIMILARS MARKET FOR TYPE II DIABETES, BY COUNTRY, 20232035 (USD MILLION) TABLE 203 ASIA PACIFIC: BIOSIMILARS MARKET FOR TYPE II DIABETES, BY COUNTRY, 20232035 (USD MILLION) TABLE 204 LATIN AMERICA: BIOSIMILARS MARKET FOR TYPE II DIABETES, BY COUNTRY, 20232035 (USD MILLION) TABLE 205 MIDDLE EAST: BIOSIMILARS MARKET FOR TYPE II DIABETES, BY REGION, 20232035 (USD MILLION) TABLE 206 BIOSIMILARS MARKET FOR OBESITY, BY REGION, 20232035 (USD MILLION) TABLE 207 NORTH AMERICA: BIOSIMILARS MARKET FOR OBESITY, BY COUNTRY, 20232035 (USD MILLION) TABLE 208 EUROPE: BIOSIMILARS MARKET FOR OBESITY, BY COUNTRY, 20232035 (USD MILLION) TABLE 209 ASIA PACIFIC: BIOSIMILARS MARKET FOR OBESITY, BY COUNTRY, 20232035 (USD MILLION) TABLE 210 LATIN AMERICA: BIOSIMILARS MARKET FOR OBESITY, BY COUNTRY, 20232035 (USD MILLION) TABLE 211 MIDDLE EAST: BIOSIMILARS MARKET FOR OBESITY, BY REGION, 20232035 (USD MILLION) TABLE 212 BIOSIMILARS MARKET FOR OTHER INDICATIONS, BY REGION, 20232035 (USD MILLION) TABLE 213 NORTH AMERICA: BIOSIMILARS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 20232035 (USD MILLION) TABLE 214 EUROPE: BIOSIMILARS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 20232035 (USD MILLION) TABLE 215 ASIA PACIFIC: BIOSIMILARS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 20232035 (USD MILLION) TABLE 216 LATIN AMERICA: BIOSIMILARS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 20232035 (USD MILLION) TABLE 217 MIDDLE EAST: BIOSIMILARS MARKET FOR OTHER INDICATIONS, BY REGION, 20232035 (USD MILLION) TABLE 218 BIOSIMILARS MARKET, BY REGION, 20232035 (USD MILLION) TABLE 219 EUROPE: KEY MACROINDICATORS TABLE 220 EUROPE: LIST OF APPROVED BIOSIMILARS, 20222025 TABLE 221 EUROPE: BIOSIMILARS MARKET, BY COUNTRY, 20232035 (USD MILLION) TABLE 222 EUROPE: BIOSIMILARS MARKET, BY DRUG CLASS, 20232035 (USD MILLION) TABLE 223 EUROPE: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 20232035 (USD MILLION) TABLE 224 EUROPE: BIOSIMILARS MARKET, BY INDICATION, 20232035 (USD MILLION) TABLE 225 GERMANY: BIOSIMILARS MARKET, BY DRUG CLASS, 20232035 (USD MILLION) TABLE 226 GERMANY: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 20232035 (USD MILLION) TABLE 227 GERMANY: BIOSIMILARS MARKET, BY INDICATION, 20232035 (USD MILLION) TABLE 228 UK: LIST OF APPROVED BIOSIMILARS, 20222025 TABLE 229 UK: BIOSIMILARS MARKET, BY DRUG CLASS, 20232035 (USD MILLION) TABLE 230 UK: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 20232035 (USD MILLION) TABLE 231 UK: BIOSIMILARS MARKET, BY INDICATION, 20232035 (USD MILLION) TABLE 232 FRANCE: BIOSIMILARS MARKET, BY DRUG CLASS, 20232035 (USD MILLION) TABLE 233 FRANCE: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 20232035 (USD MILLION) TABLE 234 FRANCE: BIOSIMILARS MARKET, BY INDICATION, 20232035 (USD MILLION) TABLE 235 ITALY: BIOSIMILARS MARKET, BY DRUG CLASS, 20232035 (USD MILLION) TABLE 236 ITALY: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 20232035 (USD MILLION) TABLE 237 ITALY: BIOSIMILARS MARKET, BY INDICATION, 20232035 (USD MILLION) TABLE 238 SPAIN: BIOSIMILARS MARKET, BY DRUG CLASS, 20232035 (USD MILLION) TABLE 239 SPAIN: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 20232035 (USD MILLION) TABLE 240 SPAIN: BIOSIMILARS MARKET, BY INDICATION, 20232035 (USD MILLION) TABLE 241 REST OF EUROPE: BIOSIMILARS MARKET, BY DRUG CLASS, 20232035 (USD MILLION) TABLE 242 REST OF EUROPE: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 20232035 (USD MILLION) TABLE 243 REST OF EUROPE: BIOSIMILARS MARKET, BY INDICATION, 20232035 (USD MILLION) TABLE 244 ASIA PACIFIC: KEY MACROINDICATORS TABLE 245 ASIA PACIFIC: BIOSIMILARS MARKET, BY COUNTRY, 20232035 (USD MILLION) TABLE 246 ASIA PACIFIC: BIOSIMILARS MARKET, BY DRUG CLASS, 20232035 (USD MILLION) TABLE 247 ASIA PACIFIC: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 20232035 (USD MILLION) TABLE 248 ASIA PACIFIC: BIOSIMILARS MARKET, BY INDICATION, 20232035 (USD MILLION) TABLE 249 JAPAN: LIST OF APPROVED BIOSIMILARS, 20222025 TABLE 250 JAPAN: BIOSIMILARS MARKET, BY DRUG CLASS, 20232035 (USD MILLION) TABLE 251 JAPAN: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 20232035 (USD MILLION) TABLE 252 JAPAN: BIOSIMILARS MARKET, BY INDICATION, 20232035 (USD MILLION) TABLE 253 CHINA: BIOSIMILARS MARKET, BY DRUG CLASS, 20232035 (USD MILLION) TABLE 254 CHINA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 20232035 (USD MILLION) TABLE 255 CHINA: BIOSIMILARS MARKET, BY INDICATION, 20232025 (USD MILLION) TABLE 256 INDIA: BIOSIMILARS APPROVED AND MARKETED, 20222025 TABLE 257 INDIA: BIOSIMILARS MARKET, BY DRUG CLASS, 20232035 (USD MILLION) TABLE 258 INDIA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 20232035 (USD MILLION) TABLE 259 INDIA: BIOSIMILARS MARKET, BY INDICATION, 20232035 (USD MILLION) TABLE 260 SOUTH KOREA: LIST OF APPROVED BIOSIMILARS, 20222025 TABLE 261 SOUTH KOREA: BIOSIMILARS MARKET, BY DRUG CLASS, 20232035 (USD MILLION) TABLE 262 SOUTH KOREA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 20232035 (USD MILLION) TABLE 263 SOUTH KOREA: BIOSIMILARS MARKET, BY INDICATION, 20232035 (USD MILLION) TABLE 264 AUSTRALIA: LIST OF APPROVED BIOSIMILARS, 20222025 TABLE 265 AUSTRALIA: BIOSIMILARS MARKET, BY DRUG CLASS, 20232035 (USD MILLION) TABLE 266 AUSTRALIA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 20232035 (USD MILLION) TABLE 267 AUSTRALIA: BIOSIMILARS MARKET, BY INDICATION, 20232035 (USD MILLION) TABLE 268 NEW ZEALAND: LIST OF APPROVED BIOSIMILARS, 20222025 TABLE 269 MALAYSIA: LIST OF APPROVED BIOSIMILARS, 20222025 TABLE 270 REST OF ASIA PACIFIC: BIOSIMILARS MARKET, BY DRUG CLASS, 20232035 (USD MILLION) TABLE 271 REST OF ASIA PACIFIC: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 20232035 (USD MILLION) TABLE 272 REST OF ASIA PACIFIC: BIOSIMILARS MARKET, BY INDICATION, 20232035 (USD MILLION) TABLE 273 NORTH AMERICA: KEY MACROINDICATORS TABLE 274 NORTH AMERICA: BIOSIMILARS MARKET, BY COUNTRY, 20232035 (USD MILLION) TABLE 275 NORTH AMERICA: BIOSIMILARS MARKET, BY DRUG CLASS, 20232035 (USD MILLION) TABLE 276 NORTH AMERICA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 20232035 (USD MILLION) TABLE 277 NORTH AMERICA: BIOSIMILARS MARKET, BY INDICATION, 20232035 (USD MILLION) TABLE 278 US: LIST OF APPROVED BIOSIMILARS, 20222025 TABLE 279 US: BIOSIMILARS MARKET, BY DRUG CLASS, 20232035 (USD MILLION) TABLE 280 US: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 20232035 (USD MILLION) TABLE 281 US: BIOSIMILARS MARKET, BY INDICATION, 20232035 (USD MILLION) TABLE 282 CANADA: LIST OF APPROVED BIOSIMILARS, 20222025 TABLE 283 CANADA: BIOSIMILARS MARKET, BY DRUG CLASS, 20232035 (USD MILLION) TABLE 284 CANADA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 20232035 (USD MILLION) TABLE 285 CANADA: BIOSIMILARS MARKET, BY INDICATION, 20232035 (USD MILLION) TABLE 286 LATIN AMERICA: KEY MACROINDICATORS TABLE 287 LATIN AMERICA: BIOSIMILARS MARKET, BY COUNTRY, 20232035 (USD MILLION) TABLE 288 LATIN AMERICA: BIOSIMILARS MARKET, BY DRUG CLASS, 20232035 (USD MILLION) TABLE 289 LATIN AMERICA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 20232035 (USD MILLION) TABLE 290 LATIN AMERICA: BIOSIMILARS MARKET, BY INDICATION, 20232035 (USD MILLION) TABLE 291 BRAZIL: BIOSIMILARS MARKET, BY DRUG CLASS, 20232035 (USD MILLION) TABLE 292 BRAZIL: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 20232035 (USD MILLION) TABLE 293 BRAZIL: BIOSIMILARS MARKET, BY INDICATION, 20232035 (USD MILLION) TABLE 294 MEXICO: BIOSIMILARS MARKET, BY DRUG CLASS, 20232035 (USD MILLION) TABLE 295 MEXICO: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 20232035 (USD MILLION) TABLE 296 MEXICO: BIOSIMILARS MARKET, BY INDICATION, 20232035 (USD MILLION) TABLE 297 REST OF LATIN AMERICA: BIOSIMILARS MARKET, BY DRUG CLASS, 20232035 (USD MILLION) TABLE 298 REST OF LATIN AMERICA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 20232035 (USD MILLION) TABLE 299 REST OF LATIN AMERICA: BIOSIMILARS MARKET, BY INDICATION, 20232035 (USD MILLION) TABLE 300 MIDDLE EAST: KEY MACROINDICATORS TABLE 301 MIDDLE EAST: BIOSIMILARS MARKET, BY REGION, 20232035 (USD MILLION) TABLE 302 MIDDLE EAST: BIOSIMILARS MARKET, BY DRUG CLASS, 20232035 (USD MILLION) TABLE 303 MIDDLE EAST: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 20232035 (USD MILLION) TABLE 304 MIDDLE EAST: BIOSIMILARS MARKET, BY INDICATION, 20232035 (USD MILLION) TABLE 305 GCC COUNTRIES: BIOSIMILARS MARKET, BY DRUG CLASS, 20232035 (USD MILLION) TABLE 306 GCC COUNTRIES: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 20232035 (USD MILLION) TABLE 307 GCC COUNTRIES: BIOSIMILARS MARKET, BY INDICATION, 20232035 (USD MILLION) TABLE 308 REST OF MIDDLE EAST: BIOSIMILARS MARKET, BY DRUG CLASS, 20232035 (USD MILLION) TABLE 309 REST OF MIDDLE EAST: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 20232035 (USD MILLION) TABLE 310 REST OF MIDDLE EAST: BIOSIMILARS MARKET, BY INDICATION, 20232035 (USD MILLION) TABLE 311 AFRICA: KEY MACROINDICATORS TABLE 312 AFRICA: BIOSIMILARS MARKET, BY DRUG CLASS, 20232035 (USD MILLION) TABLE 313 AFRICA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 20232035 (USD MILLION) TABLE 314 AFRICA: BIOSIMILARS MARKET, BY INDICATION, 20232035 (USD MILLION) TABLE 315 OVERVIEW OF MAJOR STRATEGIES DEPLOYED BY KEY PLAYERS IN BIOSIMILARS MARKET, 20222024 TABLE 316 BIOSIMILARS MARKET: DEGREE OF COMPETITION TABLE 317 BIOSIMILARS MARKET: REGION FOOTPRINT TABLE 318 BIOSIMILARS MARKET: DRUG CLASS FOOTPRINT TABLE 319 BIOSIMILARS MARKET: INDICATION FOOTPRINT TABLE 320 BIOSIMILARS MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS TABLE 321 BIOSIMILARS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SME PLAYERS, 2024 TABLE 322 BIOSIMILARS MARKET: PRODUCT APPROVALS AND LAUNCHES, JANUARY 2022APRIL 2025 TABLE 323 BIOSIMILARS MARKET: DEALS, JANUARY 2022APRIL 2025 TABLE 324 BIOSIMILARS MARKET: EXPANSIONS, JANUARY 2022 APRIL 2025 TABLE 325 SANDOZ GROUP AG: COMPANY OVERVIEW TABLE 326 SANDOZ GROUP AG: PRODUCTS OFFERED TABLE 327 SANDOZ GROUP AG: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022APRIL 2025 TABLE 328 SANDOZ GROUP AG: DEALS, JANUARY 2022APRIL 2025 TABLE 329 SANDOZ GROUP AG: EXPANSIONS, JANUARY 2022APRIL 2025 TABLE 330 SANDOZ GROUP AG: OTHER DEVELOPMENTS, JANUARY 2022APRIL 2025 TABLE 331 PFIZER INC.: COMPANY OVERVIEW TABLE 332 PFIZER INC.: PRODUCTS OFFERED TABLE 333 PFIZER INC.: PRODUCT APPROVALS, JANUARY 2022APRIL 2025 TABLE 334 PFIZER INC.: DEALS, JANUARY 2022APRIL 2025 TABLE 335 AMGEN INC.: COMPANY OVERVIEW TABLE 336 AMGEN INC.: PRODUCTS OFFERED TABLE 337 AMGEN INC.: PRODUCTS IN PIPELINE TABLE 338 AMGEN INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022APRIL 2025 TABLE 339 AMGEN INC.: DEALS, JANUARY 2022APRIL 2025 TABLE 340 AMGEN INC.: EXPANSIONS, JANUARY 2022APRIL 2025 TABLE 341 CELLTRION INC.: COMPANY OVERVIEW TABLE 342 CELLTRION INC.: PRODUCTS OFFERED TABLE 343 CELLTRION INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022APRIL 2025 TABLE 344 CELLTRION INC.: DEALS, JANUARY 2022APRIL 2025 TABLE 345 BIOCON: COMPANY OVERVIEW TABLE 346 BIOCON: PRODUCTS OFFERED TABLE 347 BIOCON: PRODUCT APPROVALS, JANUARY 2022APRIL 2025 TABLE 348 BIOCON: DEALS, JANUARY 2022APRIL 2025 TABLE 349 BIOCON: OTHER DEVELOPMENTS, JANUARY 2022APRIL 2025 TABLE 350 DR
For patients specifically interested in maximizing results with newer options like tirzepatidewhich has been shown to produce greater weight loss than traditional GLP-1 therapiesNalenas positioning around advanced, clinician-guided protocols may offer a more specialized and results-driven experience compared to Mochis more generalized platform
